☆ 4.7 Article

Differences in the pharmacokinetics and steady-state blood concentrations of orally administered lenvatinib in adult and juvenile rats

FRONTIERS IN PHARMACOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Medicine, Research & Experimental

The impact of individual human cytochrome P450 enzymes on oxidative metabolism of anticancer drug lenvatinib

Katarina Vavrova et al.

Summary: Lenvatinib, a small molecule tyrosine kinase inhibitor, shows good inhibitory effects in various carcinomas, especially in thyroid cancer. Metabolites of lenvatinib have been identified through in vitro studies using human hepatic microsomes and recombinant CYPs, with CYP3A4 and CYP1A1 playing significant roles in the metabolism of lenvatinib. Further research on drug-drug interactions and CYP modulators is needed for personalized therapy with TKIs.

BIOMEDICINE & PHARMACOTHERAPY (2022)

Add to Collection

Article Chemistry, Medicinal

Species Difference in the Metabolism of Mulberrin <i>in Vitro</i> and Its Inhibitory Effect on Cytochrome P450 and UDP-Glucuronosyltransferase Enzymes

Jiayin Hu et al.

CHEMICAL & PHARMACEUTICAL BULLETIN (2022)

Add to Collection

Article Medicine, General & Internal

Socioeconomic inequalities in cancer incidence and access to health services among children and adolescents in China: a cross-sectional study

Xin Ni et al.

LANCET (2022)

Add to Collection

Article Chemistry, Multidisciplinary

Species differences in the CYP3A-catalyzed metabolism of TPN729, a novel PDE5 inhibitor

Qian-qian Tian et al.

Summary: The study revealed significant species differences in the relative abundance of the main metabolite M3, with a much higher plasma exposure of M3 compared to TPN729 in humans. The research also demonstrated that CYP3A was responsible for TPN729 metabolism and M3 formation in humans, with a seven-fold disparity in the catalyzing capability of CYP3A4 for M3 formation between species. M3 was found to be an active metabolite with pharmacological contribution equal to that of TPN729 in humans.

ACTA PHARMACOLOGICA SINICA (2021)

Add to Collection

Review Oncology

Is it possible to halve the incidence of liver cancer in China by 2050?

Ju-Fang Shi et al.

Summary: A substantial proportion of liver cancers are caused by chronic infections of hepatitis B and C. The global mortality rate for liver cancer remains high, with varying trends in different countries. China has historically had a significant burden of liver cancer, but recent data show a decline in liver cancer incidence in the country.

INTERNATIONAL JOURNAL OF CANCER (2021)

Add to Collection

Article Chemistry, Analytical

UPLC-MS/MS method for the determination of Lenvatinib in rat plasma and its application to drug-drug interaction studies

Yanjun Cui et al.

Summary: The combination of traditional Chinese medicine preparation Wuzhi capsule (WZC) and multitargeted tyrosine kinase inhibitor Lenvatinib (LEN) may impact the pharmacokinetic parameters of LEN in rats and increase the plasma concentration of LEN. An UPLC-MS/MS method developed in this study serves as a valuable tool for studying drug-drug interactions.

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2021)

Add to Collection

Review Oncology

Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib

Marie Decraecker et al.

Summary: The use of atezolizumab and bevacizumab in advanced hepatocellular carcinomas has changed the therapeutic approach, emphasizing the need to redefine the role of tyrosine kinase inhibitors, particularly lenvatinib. This review aims to explore potential indications for lenvatinib treatment in different clinical scenarios and highlights the evolving landscape of systemic treatment options in hepatocellular carcinoma.

CANCERS (2021)

Add to Collection

Article Oncology

Hepatobiliary Cancers, Version 2.2021

Al B. Benson III et al.

Summary: The NCCN Guidelines for Hepatobiliary Cancers provide recommendations for screening, diagnosis, staging, treatment, and management of HCC, gallbladder cancer, and cancer of the bile ducts. A multidisciplinary evaluation is crucial for determining optimal treatment strategies, with significant advancements in systemic treatment of HCC beyond traditional options like sorafenib.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Add to Collection

Article Oncology

Cancer statistics, 2020

Rebecca L. Siegel et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2020)

Add to Collection

Review Gastroenterology & Hepatology

Molecular therapies for HCC: Looking outside the box

Sandrine Faivre et al.

JOURNAL OF HEPATOLOGY (2020)

Add to Collection

Review Biochemistry & Molecular Biology

The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects

Weiwei Tang et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)

Add to Collection

Article Multidisciplinary Sciences

Age-associated changes of cytochrome P450 and related phase-2 gene/proteins in livers of rats

Shang-Fu Xu et al.

PEERJ (2019)

Add to Collection

Review Gastroenterology & Hepatology

Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west

Jian Lu et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)

Add to Collection

Review Oncology

Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma

Ziyu Liu et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)

Add to Collection

Article Public, Environmental & Occupational Health

Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries

Hongmei Zeng et al.

LANCET GLOBAL HEALTH (2018)

Add to Collection

Article Chemistry, Analytical

Validation of a Liquid Chromatography-Tandem Mass Spectrometric Assay for Quantitative Analysis of Lenvatinib in Human Plasma

Tomoko Ogawa-Morita et al.

INTERNATIONAL JOURNAL OF ANALYTICAL CHEMISTRY (2017)

Add to Collection

Review Oncology

Global Cancer Incidence and Mortality Rates and Trends-An Update

Lindsey A. Torre et al.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2016)

Add to Collection

Article Pharmacology & Pharmacy

Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer

Anubha Gupta et al.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)

Add to Collection

Article Oncology

Cancer Statistics in China, 2015

Wanqing Chen et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2016)

Add to Collection

Letter Medicine, General & Internal

Lenvatinib in Radioiodine-Refractory Thyroid Cancer

Hyo Jin Lee et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Review Genetics & Heredity

Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions

C. Arimany-Nardi et al.

PHARMACOGENOMICS JOURNAL (2015)

Add to Collection

Article Multidisciplinary Sciences

Impact of Diet-Induced Obesity and Testosterone Deficiency on the Cardiovascular System: A Novel Rodent Model Representative of Males with Testosterone-Deficient Metabolic Syndrome (TDMetS)

Daniel G. Donner et al.

PLOS ONE (2015)

Add to Collection

Article Pharmacology & Pharmacy

Effect of Rifampicin on the Pharmacokinetics of Lenvatinib in Healthy Adults

Robert C. Shumaker et al.

CLINICAL DRUG INVESTIGATION (2014)

Add to Collection

Review Pharmacology & Pharmacy

Organic Cation Transporter OCTs (SLC22) and MATEs (SLC47) in the Human Kidney

Hideyuki Motohashi et al.

AAPS JOURNAL (2013)

Add to Collection

Article Gastroenterology & Hepatology

Expression of SLC22A1 Variants May Affect the Response of Hepatocellular Carcinoma and Cholangiocarcinoma to Sorafenib

Elisa Herraez et al.

HEPATOLOGY (2013)

Add to Collection

Article Oncology

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

D. S. Boss et al.

BRITISH JOURNAL OF CANCER (2012)

Add to Collection

Article Oncology

Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors

Kazuhiko Yamada et al.

CLINICAL CANCER RESEARCH (2011)

Add to Collection

Review Gastroenterology & Hepatology

Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents

M. Chaparro et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.